David W Hedley

David W Hedley, MD

Our main goal is to develop effective cancer treatments based on a deeper understanding of the molecular processes occurring in human cancers. The laboratory seeks to close the gap between basic cancer research and the early clinical trials programs at Princess Margaret Hospital. To this end, we have access to a wide range of exciting new anticancer agents that are just entering early human clinical trials. Areas of emphasis include the use of xenograft models including primary orthotopic implants from human cancers, and the development of analytical methods for studying complex molecular interactions at the single cell level.

We have particular expertise in the development and application of advanced methodology based on the use of flow cytometry and digital fluorescence microscopy. This technology development is done in close collaboration with members of the Physics Division, the Department of Pathology, and the STTARR Program. Areas of current interest include the effects of tumour hypoxia on survival signaling in solid tumours; the analysis of complex signaling interactions in hematological malignancies based on multiparametric flow cytometry; and the role of aberrant signaling pathways in the growth of pancreatic cancers.

In addition to using model systems based on tissue culture and human tumour xenografts, the laboratory is also involved in the analysis of samples obtained from patients on clinical trials involving molecular cancer therapeutics.
Eur J Immunol. 2017 Oct;47(10):1584-1797
Cossarizza A, Chang HD, Radbruch A, Andrä I, Annunziato F, Bacher P, Barnaba V, Battistini L, Bauer WM, Baumgart S, Becher B, Beisker W, Berek C, Blanco A, Borsellino G, Boulais PE, Brinkman RR, Büscher M, Busch DH, Bushnell TP, Cao X, Cavani A,...
J Gastrointest Oncol. 2017 Apr;8(2):352-360
Doherty MK, McNamara MG, Aneja P, McInerney E, Moignard S, Horgan AM, Jiang H, Panzarella T, Jang R, Dhani N, Hedley D, Knox JJ
Cytometry A. 2017 Feb 03;:
Chang Q, Ornatsky OI, Siddiqui I, Loboda A, Baranov VI, Hedley DW
PLoS One. 2016;11(12):e0167272
Lohse I, Kumareswaran R, Cao P, Pitcher B, Gallinger S, Bristow RG, Hedley DW
Oncotarget. 2016 Nov 25;:
Lohse I, Mason JM, Cao PJ, Pintilie M, Bray MR, Hedley DW
Oncotarget. 2016 Nov 25;:
Marie-Egyptienne DT, Chaudary N, Kalliomäki T, Hedley DW, Hill RP
Br J Cancer. 2016 Nov 22;:
Chaudary N, Pintilie M, Hedley D, Hill RP, Milosevic M, Mackay H
Sci Rep. 2016 Nov 04;6:36641
Chang Q, Ornatsky OI, Siddiqui I, Straus R, Baranov VI, Hedley DW
Phys Med Biol. 2016 Nov 21;61(22):7957-7974
Taylor E, Yeung I, Keller H, Wouters BG, Milosevic M, Hedley DW, Jaffray DA